Q1 2024 EPS Estimates for OptimizeRx Co. Decreased by William Blair (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Analysts at William Blair reduced their Q1 2024 EPS estimates for shares of OptimizeRx in a research report issued to clients and investors on Tuesday, April 16th. William Blair analyst R. Daniels now forecasts that the company will post earnings of ($0.34) per share for the quarter, down from their previous forecast of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.59) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

Several other research firms have also commented on OPRX. JMP Securities reiterated a “market outperform” rating and issued a $15.00 price objective on shares of OptimizeRx in a research report on Tuesday. Barclays began coverage on shares of OptimizeRx in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a report on Monday, April 1st. Finally, Stifel Nicolaus restated a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $15.86.

OptimizeRx Trading Down 4.3 %

OptimizeRx stock opened at $9.53 on Thursday. OptimizeRx has a 52 week low of $6.92 and a 52 week high of $16.65. The firm’s 50-day simple moving average is $13.48 and its 200 day simple moving average is $11.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of OptimizeRx by 2.6% during the 3rd quarter. BlackRock Inc. now owns 2,773,502 shares of the company’s stock valued at $41,105,000 after acquiring an additional 70,139 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of OptimizeRx by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 1,115,086 shares of the company’s stock valued at $42,049,000 after acquiring an additional 32,310 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of OptimizeRx by 75.8% during the 3rd quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock valued at $6,088,000 after acquiring an additional 337,303 shares during the last quarter. State Street Corp increased its stake in shares of OptimizeRx by 3.0% during the 3rd quarter. State Street Corp now owns 679,698 shares of the company’s stock valued at $10,073,000 after acquiring an additional 19,815 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in shares of OptimizeRx during the 3rd quarter valued at about $4,323,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.